Dutcher J P
New York Medical College, Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA.
Curr Oncol Rep. 2001 Jul;3(4):353-8. doi: 10.1007/s11912-001-0089-1.
Angiogenesis is a process that is central to tumor growth and survival. This process is stimulated by a variety of intrinsic growth factors such as vascular endothelial growth factor, basic and acid fibroblast growth factor, and platelet-derived endothelial growth factor, among others. The process of neo-angiogenesis has been shown to be key in the proliferation of melanoma, and primarily believed to be so in the metastatic process. Biologic markers of angiogenesis are being evaluated for correlations with prognosis and biologic behavior of the tumor. These markers may also indicate susceptibility to targeted therapy. Interruption of the tumor-sustaining process of angiogenesis has become a major focus of anticancer drug development. Promising agents are in both preclinical and clinical development. Several may prove to be clinically important.
血管生成是肿瘤生长和存活的核心过程。这一过程受到多种内在生长因子的刺激,如血管内皮生长因子、碱性和酸性成纤维细胞生长因子以及血小板衍生的内皮生长因子等。新生血管生成过程已被证明是黑色素瘤增殖的关键,并且主要被认为在转移过程中也是如此。目前正在评估血管生成的生物标志物与肿瘤预后和生物学行为的相关性。这些标志物也可能表明对靶向治疗的敏感性。中断维持肿瘤生长的血管生成过程已成为抗癌药物研发的主要焦点。有前景的药物正处于临床前和临床开发阶段。其中几种可能被证明具有临床重要性。